Asthma and Airway Obstruction Cohort: Clinicobiological Cohort Follow-up

{
"level_sex_clusion_I": [
{
"value": "Male",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D008297"
}
},
{
"value": "Female",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D005260"
}
}
],
"level_age_clusion_I": [
{
"value": "Young Adult (19 to 24 years)",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D055815"
}
},
{
"value": "Adult (25 to 44 years)",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D000328"
}
},
{
"value": "Middle Aged (45 to 64 years)",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D008875"
}
},
{
"value": "Aged (65 to 79 years)",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D000368"
}
}
],
"level_type_clusion_I": [
"Patients population"
],
"level_type_clusion_other": "",
"clusion_I": "Two cohorts: one with asthmatics and one with individuals affected by COBP; subjects included between the ages of 18 and 80 years old. Asthma cohort: including patients who are non-smokers and smokers with compatible clinical history and individuals with a reversible obstructive airway disease, based on a FEV1\/CV <75% and an FEV1 baseline value improvement of 12% or 200 ml after inhalation of 400 µg of Salbutamol. COBP cohort: including patients who are smokers (>10 packets per year) presenting with an obstructive airway disease (FEV1\/CV <75%) and an FEV1 improvement of less than 10% after inhalation of 200 µg of Salbutamol.",
"clusion_E": ""
}